A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis
Sponsor: University of York
Listed as NCT03969134, this PHASE2 trial focuses on Leishmaniasis, Cutaneous and remains completed. Sponsored by University of York, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Oct 2022 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of York
For direct contact, visit the study record on ClinicalTrials.gov .